Methylene blue / LDH Cancer Research Results

M-Blu, Methylene blue: Click to Expand ⟱
Features:
Methylene blue (MB), also known as methylthioninium chloride, is a thiazine dye that can be used as a medication, and can be administered orally, subcutaneously or intravenously.
Mainly used to treat methemoglobinemia by chemically reducing the ferric iron in hemoglobin to ferrous iron
Methylene blue is commonly used in medical practice, especially as a dye in microbiological staining
Antidote in cyanide poisoning: an oxidation-reduction indicator: an antiseptic

Pathways:
- may increases the oxygen consumption of normal tissues having aerobic glycolysis, and of tumors
- generate reactive oxygen species (ROS) upon light activation
-effects on mitochondrial metabolism may contribute to modulation of apoptosis and energy metabolism in cancer cells.
-can affect the generation of reactive oxygen species.
-Historically, it was used in patients with urinary tract infection
-MB has also been used as a tracer for cancer diagnosis and as a photosensitizer for cancer treatment
-shifts redox balance and can promote OXPHOS over glycolysis in some models(reverse Warburg effect)
-can cross BBB and reach brain at concentrations 10 times higher than that in the circulation
-causes shift from shift from glycolysis to oxidative phosphorylation.
-reduces glutathione reductase GSR (an enzyme of glutathione metabolism), context- and concentration-dependent

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Mitochondrial redox cycling (electron shuttle) Redox modulation; NADH oxidation ↑ (context) Mitochondrial efficiency ↑ at low doses (reported) P, R Bioenergetic modulation MB can accept electrons from NADH and donate downstream in the ETC; effects are dose-dependent and context-specific.
2 OXPHOS vs glycolysis balance Shift toward oxidative metabolism reported in some tumor models Improved mitochondrial coupling (low dose) R Metabolic reprogramming Sometimes described as “Warburg reversal,” but more accurately a redox/respiratory modulation that varies by system.
3 ROS modulation (biphasic) ROS ↑ at higher doses; apoptosis ↑ (reported) ROS ↓ or stabilized at lower doses P, R Redox destabilization (dose-dependent) Acts antioxidant at low concentrations; can become pro-oxidant as concentration increases.
4 Mitochondrial membrane potential (ΔΨm) ΔΨm collapse at higher doses (reported) Stabilization possible at low doses R Mitochondrial stress High-dose exposure can impair mitochondrial integrity and promote apoptosis.
5 Intrinsic apoptosis signaling Caspases ↑; apoptosis ↑ (reported in vitro) ↔ G Cell death execution Generally downstream of ROS and mitochondrial perturbation.
6 Photodynamic ROS generation (light-activated) ROS ↑↑ when photoactivated Localized ROS if illuminated P Photoactivated cytotoxicity Distinct mechanism: MB acts as a photosensitizer under light exposure.
7 Glutathione system modulation (GSR / redox enzymes) Redox enzyme modulation reported (model-dependent) Redox buffering alteration possible R Redox regulation Some reports show interaction with glutathione metabolism; not a dominant universal pathway.
8 Blood–brain barrier penetration — CNS accumulation (high tissue levels) P, R Pharmacokinetic property MB crosses the BBB and can accumulate in brain tissue at higher concentrations than plasma.
9 Monoamine oxidase (MAO) inhibition — MAO-A inhibition (clinically relevant) R Off-target pharmacology Important interaction risk with SSRIs/SNRIs (serotonin syndrome).
10 Safety constraints (G6PD deficiency; serotonin syndrome) — Hemolysis risk (G6PD); serotonin toxicity risk — Clinical risk management Well-established safety considerations in clinical use.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid redox cycling; photoactivation)
  • R: 30 min–3 hr (mitochondrial and redox signaling shifts)
  • G: >3 hr (apoptosis/autophagy outcomes)
LDH, Lactate Dehydrogenase: Click to Expand ⟱
Source:
Type:
LDH is a general term that refers to the enzyme that catalyzes the interconversion of lactate and pyruvate. LDH is a tetrameric enzyme, meaning it is composed of four subunits.
LDH refers to the enzyme as a whole, while LDHA specifically refers to the M subunit. Elevated LDHA levels are often associated with poor prognosis and aggressive tumor behavior, similar to elevated LDH levels.
leakage of LDH is a well-known indicator of cell membrane integrity and cell viability [35]. LDH leakage results from the breakdown of the plasma membrane and alterations in membrane permeability, and is widely used as a cytotoxicity endpoint.

However, it's worth noting that some studies have shown that LDHA is a more specific and sensitive biomarker for cancer than total LDH, as it is more closely associated with the Warburg effect and cancer metabolism.

Dysregulated LDH activity contributes significantly to cancer development, promoting the Warburg effect (Chen et al., 2007), which involves increased glucose uptake and lactate production, even in the presence of oxygen, to meet the energy demands of rapidly proliferating cancer cells (Warburg and Minami, 1923; Dai et al., 2016b). LDHA overexpression favors pyruvate to lactate conversion, leading to tumor microenvironment acidification and aiding cancer progression and metastasis.

Inhibitors:
Flavonoids, a group of polyphenols abundant in fruit, vegetables, and medicinal plants, function as LDH inhibitors.
LDH is used as a clinical biomarker for Synthetic liver function, nutrition

Tier A — Direct LDH Enzyme Inhibitors (Validated Catalytic Inhibition)

Rank Compound Type LDH Target Potency Level Primary Effect Notes
1 NCI-006 Research drug LDHA / LDHB High (in vivo active) Potent glycolysis suppression Modern benchmark LDH inhibitor used in metabolic oncology models.
2 (R)-GNE-140 Research drug LDHA (±LDHB) High (nM range reported) Lactate production ↓ Widely used experimental LDH inhibitor.
3 FX11 Research drug LDHA High (μM range) Metabolic crisis in LDHA-dependent tumors Classic LDHA inhibitor; often increases ROS secondary to metabolic stress.
4 Oxamate Tool compound LDH (pyruvate-competitive) Moderate (mM cellular use) Reduces lactate flux Classical LDH inhibitor; requires high concentrations in cells.
5 Gossypol Natural product derivative LDHA Moderate–High Glycolysis inhibition Also has other targets; safety considerations apply.
6 Galloflavin Natural compound LDH isoforms Moderate Lactate production ↓ One of the better-supported “natural-like” LDH inhibitors.

Tier B — Indirect LDH-Axis Modulators (Glycolysis / Lactate Reduction Without Confirmed Direct Catalytic Inhibition)

Rank Compound Mechanism Type LDH Claim Type Primary Axis Notes / Caution
1 Lonidamine MCT/MPC modulation Lactate axis inhibition Metabolic transport blockade Better classified as lactate/pyruvate transport modulator.
2 Stiripentol Repurposed drug LDH pathway modulation Metabolic axis modulation Emerging oncology interest; primarily neurological drug.
3 Quercetin Flavonoid Reported LDH inhibition (mixed evidence) NF-κB / PI3K modulation Often LDH-release confusion; direct enzymatic proof limited.
4 Ursolic acid Triterpenoid Reported LDH interaction Warburg modulation More credible as metabolic signaling modulator.
5 Fisetin Flavonoid Docking / indirect reports Apoptosis / survival signaling Enzyme inhibition not well validated.
6 Resveratrol Polyphenol Indirect glycolysis suppression AMPK / HIF-1α modulation Reduces lactate via upstream signaling.
7 Curcumin Polyphenol Indirect LDH expression modulation Inflammation + metabolic signaling Bioavailability limits translational strength.
8 Berberine Alkaloid Indirect metabolic modulation AMPK activation Closer to metformin-like metabolic pressure.
9 Honokiol Lignan Indirect glycolysis effects Survival pathway suppression Not validated as catalytic LDH inhibitor.
10 Silibinin Flavonolignan Mixed / indirect reports Inflammation + metabolic axis Often misclassified as LDH inhibitor.
11 Kaempferol Flavonoid Often LDH-release marker confusion Glucose transport / signaling Do not list as direct LDH inhibitor without enzyme data.
12 Oleanolic acid / Limonin / Allicin / Taurine Natural compounds Weak / indirect evidence General metabolic modulation Should not be categorized as true LDH inhibitors.

Tier A = Direct catalytic LDH inhibition (enzyme-level validation).
Tier B = Indirect lactate reduction or glycolytic modulation without strong catalytic inhibition evidence.
Important: LDH release assays (cell damage marker) are not proof of LDH enzymatic inhibition.



Scientific Papers found: Click to Expand⟱
2531- M-Blu,    Anticancer activity of methylene blue via inhibition of heat shock protein 70
- in-vitro, Lung, A549 - in-vivo, NA, NA
tumCV↓, HSP70/HSPA5↓, LDH↓, SOD↑,
2534- M-Blu,  doxoR,  PDT,    Methylene Blue-Mediated Photodynamic Therapy in Combination With Doxorubicin: A Novel Approach in the Treatment of HT-29 Colon Cancer Cells
- in-vitro, CRC, HT-29
LDH↑, ROS↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,   SOD↑, 1,  

Core Metabolism/Glycolysis ⓘ

LDH↓, 1,   LDH↑, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

HSP70/HSPA5↓, 1,  

Clinical Biomarkers ⓘ

LDH↓, 1,   LDH↑, 1,  
Total Targets: 8

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: LDH, Lactate Dehydrogenase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:12  Target#:906  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page